HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC
Shots:
- The company reported preliminary results from the P-II (SAVANNAH) trial evaluating savolitinib + Tagrisso in 294 patients with EGFRm, LA, or metastatic NSCLC with MET overexpression & amplification at 80+ centers globally, incl. US, Canada, EU, South America & Asia
- In P-II trial, EGFRm NSCLC patients with high levels of MET overexpression or amplification/ high levels of MET who were not treated with prior CT/ patients whose tumors did not show high levels of MET showed an ORR (49%/52%/9%); m-DoR (9.3/ 9.6/6.9mos.); m-PFS (7.1/7.2/2.8mos.); DCR (74%/75%/43%), respectively
- The safety profile was consistent with the known profiles with no new safety signals, 45% experienced grade ≥3 AEs, Savolitinib was marketed under the brand name Orpathys in China
Ref: HUTCHMED | Image: HUTCHMED
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
